Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI

FASEB Journal

Volumn 22, Issue 7, 2008, Pages 2445-2451

  Zhao, Dawen ^a   Richer, Edmond ^a   Antich, Peter P ^a   Mason, Ralph P ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Breast tumor; Pharmacodynamics; Vascular disrupting agent; Vascular targeting agent

Indexed keywords

COMBRETASTATIN A4 PHOSPHATE; INDOLE DERIVATIVE; LUCIFERIN SUBSTRATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; BREAST CANCER; CONTROLLED STUDY; HISTOLOGY; HUMAN; HUMAN CELL; INFRARED RADIATION; KINETICS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENES, REPORTER; HUMANS; IMMUNOHISTOCHEMISTRY; LUMINESCENCE; MAGNETIC RESONANCE IMAGING; MICE; MICE, NUDE; STILBENES; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA; MUS;

EID: 46749103224     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.07-103713     Document Type: Article

References (39)

1. Li, J. Z., Holman, D., Li, H. W., Liu, A. H., Beres, B., Hankins, G. R., and Helm, G. A. (2005) Long-term tracing of adenoviral expression in rat and rabbit using luciferase imaging. J. Gene Med. 7, 792-802
2. Rice, B. W., Cable, M. D., and Nelson, M. B. (2001) In vivo imaging of light-emitting probes. J. Biomed. Optics 6, 432-440
3. Thorne, S. H., and Contag, C. H. (2005) Using in vivo bioluminescence imaging to shed light on cancer biology. Proc. IEEE 93, 750-762
4. Jenkins, D. E., Yu, S. F., Hornig, Y. S., Purchio, T., and Contag, P. R. (2003) In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer. Clin. Exp. Metastasis 20, 745-756
5. Szentirmai, O., Baker, C. H., Lin, N., Szucs, S., Takahashi, M., Kiryu, S., Kung, A. L., Mulligan, R. C., and Carter, B. S. (2006) Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect. Neurosurg. 58, 365-372
6. Dikmen, Z. G., Gellert, G. C., Jackson, S., Gryaznov, S., Tressler, R., Dogan, P., Wright, W. E., and Shay, J. W. (2005) In vivo inhibition of lung cancer by GRN163l: a novel human telomerase inhibitor. Cancer Res. 65, 7866-7873
7. Hsu, A. R., Cai, W. B., Veeravagu, A., Mohamedali, K. A., Chen, K., Kim, S., Vogel, H., Hou, L. C., Tse, V., Rosenblum, M. G., and Chen, X. Y. (2007) Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF(121)/rGel. J. Nucl. Med. 48, 445-454
8. Mi, J., Sarraf-Yazdi, S., Zhang, X., Cao, Y., Dewhirst, M. W., Kontos, C. D., Li, C.-Y., and Clary, B. M. (2006) A comparison of antiangiogenic therapies for the prevention of liver metastases. J. Surg. Res. 131, 97-104
9. Rehemtulla, A., Stegman, L. D., Cardozo, S. J., Gupta, S., Hall, D. E., Contag, C. H., and Ross, B. D. (2000) Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia 2, 491-495
10. Verneris, M. R., Arshi, A., Edinger, M., Kornacker, M., Natkunam, Y., Karami, M., Cao, Y. A., Marina, N., Contag, C. H., and Negrin, R. S. (2005) Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells. Clin. Cancer Res. 11, 4561-4570
11. Bollinger, R. A. (2006) Evaluation of the light emission kinetics in luciferin/luciferase-based in vivo bioluminescence imaging for guidance in the development of small animal imaging study design. Ph.D. dissertation, University of Texas Southwestern
12. Paroo, Z., Bollinger, R. A., Braasch, D. A., Richer, E., Corey, D. R., Antich, P. P., and Mason, R. P. (2004) Validating bioluminescence imaging as a high-throughput, quantitative modality for assessing tumor burden. Mol. Imag. 3, 117-124
13. Contag, C. H., and Ross, B. D. (2002) It's not just about anatomy: in vivo bioluminescence imaging as an eyepiece into biology. JMRI 16, 378-387
14. Lipshutz, G. S., Gruber, C. A., Cao, Y., Hardy, J., Contag, C. H., and Gaensler, K. M. (2001) In utero delivery of adeno-associated viral vectors: intraperitoneal gene transfer produces long-term expression. Mol. Ther. 3, 284-292
15. Folkman, J. (2003) Angiogenesis and apoptosis. Semin. Cancer Biol. 13, 159-167
16. Denekamp, J. (1990) Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev. 9, 267-282
17. Horsman, M. R., and Siemann, D. W. (2006) Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res. 66, 11520-11539
18. Siemann, D. W., Bibby, M. C., Dark, G. G., Dicker, A. P., Eskens, F. A., Horsman, M. R., Marme, D., and Lorusso, P. M. (2005) Differentiation and definition of vascular-targeted therapies. Clin. Cancer Res. 11, 416-420
19. Thorpe, P. E. (2004) Vascular targeting agents as cancer therapeutics. Clin. Cancer Res. 10, 415-427
20. Dark, G. G., Hill, S. A., Prise, V. E., Tozer, G. M., Pettit, G. R., and Chaplin, D. J. (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57, 1829-1834
21. Kragh, M., Quistorff, B., Horsman, M. R., and Kristjansen, P. E. (2002) Acute effects of vascular modifying agents in solid tumors assessed by noninvasive laser Doppler flowmetry and near infrared spectroscopy. Neoplasia 4, 263-267
22. Goertz, D. E., Yu, J. L., Kerbel, R. S., Burns, P. N., and Foster, F. S. (2002) High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. Cancer Res. 62, 6371-6375
23. Tozer, G. M., Prise, V. E., Wilson, J., Locke, R. J., Vojnovic, B., Stratford, M. R., Dennis, M. F., and Chaplin, D. J. (1999) Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues Cancer Res. 59, 1626-1163
24. Galbraith, S. M., Maxwell, R. J., Lodge, M. A., Tozer, G. M., Wilson, J., Taylor, N. J., Stirling, J. J., Sena, L., Padhani, A. R., and Rustin, G. J. S. (2003) Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J. Clin. Oncol. 21, 2831-2842
25. Rustin, G. J., Galbraith, S. M., Anderson, H., Stratford, M., Folkes, L. K., Sena, L., Gumbrell, L., and Price, P. M. (2003) Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J. Clin. Oncol. 21, 2815-2822
26. Robinson, S. P., McIntyre, D. J., Checkley, D., Tessier, J. J., Howe, F. A., Griffiths, J. R., Ashton, S. E., Ryan, A. J., Blakey, D. C., and Waterton, J. C. (2003) Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br. J. Cancer 88, 1592-1597
27. Prise, V. E., Honess, D. J., Stratford, M. R. L., Wilson, J., and Tozer, G. M. (2002) The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int. J. Oncol. 21, 717-726
28. Padhani, A. R. (2003) MRI for assessing antivascular cancer treatments. Br. J. Radiol. 76, S60-S80
29. McIntyre, D. J. O., Robinson, S. P., Howe, F. A., Griffiths, J. R., Ryan, A. J., Blakey, D. C., Peers, I. S., and Waterton, J. C. (2004) Single dose of the antivascular agent, ZD6126 (N-acetylcoichinol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor model. Neoplasia 6, 150-157
30. Zhao, D., Jiang, L., Hahn, E. W., and Mason, R. P. (2005) Tumor physiological response to combretastatin A4 phosphate assessed by MRI. Int. J. Radiat. Oncol. Biol. Phys. 62, 872-880
31. Anderson, H. L., Yap, J. T., Miller, M. P., Robbins, A., Jones, T., and Price, P. M. (2003) Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J. Clin. Oncol. 21, 2823-2830
32. Maxwell, R. J., Wilson, J., Prise, V. E., Vojnovic, B., Rustin, G. J., Lodge, M. A., and Tozer, G. M. (2002) Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed. 15, 89-98
33. Beauregard, D. A., Pedley, R. B., Hill, S. A., and Brindle, K. M. (2002) Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS. NMR Biomed. 15, 99-105
34. Ng, Q.-S., Goh, V., Carnell, D., Meer, K., Padhani, A. R., Saunders, M. I., and Hoskin, P. J. (2007) Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 67, 1375-1380
35. Ley, C. D., Horsman, M. R., and Kristjansen, P. E. G. (2007) Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure. Neoplasia 9, 108-112
36. Kim, J. G., Liu, H., Zhao, D., and Mason, R. P. (2006) Acute effects of combretastatin A4 phosphate on breast tumor hemodynamics monitored by near infrared spectroscopy. Biomed. Opt. Topical Meeting (Fort Lauderdale) 19-23
37. Tozer, G. M., Prise, V. E., Wilson, J., Cemazar, M., Shan, S. Q., Dewhirst, M. W., Barber, P. R., Vojnovic, B., and Chaplin, D. J. (2001) Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. 61, 6413-6422
38. Wang, Y., Sun, Z. D., Peng, J. C., and Zhan, L. S. (2007) Bioluminescent imaging of hepatocellular carcinoma in live mice. Biotechnol. Lett. 29, 1665-1670
39. Chen, C.-C., Hwang, J.-J., Ting, G., Tseng, Y.-L., Wang, S.-J., and Whang-Peng, J. (2007) Monitoring and quantitative assessment of tumor burden using in vivo bioluminescence imaging. Nucl. Instruments Methods Phys. Res. A Accelerators Spectrometers Detectors Assoc. Equip. 571, 437-441